Monika Głuch-Lutwin1, Kinga Sałaciak2, Alicja Gawalska3, Marek Jamrozik3, Joanna Sniecikowska3, Adrian Newman-Tancredi4, Marcin Kołaczkowski3, Karolina Pytka5. 1. Department of Pharmacobiology, Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland. 2. Department of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland. 3. Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland. 4. Neurolixis SAS, Castres, France. 5. Department of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland. karolina.pytka@uj.edu.pl.
Abstract
RATIONALE: The prevalence of depression is ever-increasing throughout the population. However, available treatments are ineffective in around one-third of patients and there is a need for more effective and safer drugs. OBJECTIVES: The antidepressant-like and procognitive effects of the "biased agonists" F15599 (also known as NLX-101) which preferentially targets postsynaptic 5-HT1A receptors and F13714, which targets 5-HT1A autoreceptors, were investigated in mice. METHODS: Antidepressant-like properties of the compounds and their effect on cognitive functions were assessed using the forced swim test (FST) and the novel object recognition (NOR), respectively. Next, we induced a depressive-like state by an unpredictable chronic mild stress (UCMS) procedure to test the compounds' activity in the depression model, followed by measures of sucrose preference, FST, and locomotor activity. Levels of phosphorylated cyclic AMP response element-binding protein (p-CREB) and phosphorylated extracellular signal-regulated kinase (p-ERK1/2) were also determined. RESULTS: F15599 reduced immobility time in the FST over a wider dose-range (2 to 16 mg/kg po) than F13714 (2 and 4 mg/kg po), suggesting accentuated antidepressant-like properties in mice. F15599 did not disrupt long-term memory consolidation in the NOR at any dose tested, while F13714 impaired memory formation, notably at higher doses (4-16 mg/kg). In UCMS mice, a single administration of F15599 and F13714 was sufficient to robustly normalize depressive-like behavior in the FST but did not rescue disrupted sucrose preference. Both F15599 and F13714 rescued cortical and hippocampal deficits in p-ERK1/2 levels of UCMS mice but did not influence the p-CREB levels. CONCLUSIONS: Our studies showed that 5-HT1A receptor biased agonists such as F13714 and especially F15599, due to its less pronounced side effects, might have potential as fast-acting antidepressants.
RATIONALE: The prevalence of depression is ever-increasing throughout the population. However, available treatments are ineffective in around one-third of patients and there is a need for more effective and safer drugs. OBJECTIVES: The antidepressant-like and procognitive effects of the "biased agonists" F15599 (also known as NLX-101) which preferentially targets postsynaptic 5-HT1A receptors and F13714, which targets 5-HT1A autoreceptors, were investigated in mice. METHODS: Antidepressant-like properties of the compounds and their effect on cognitive functions were assessed using the forced swim test (FST) and the novel object recognition (NOR), respectively. Next, we induced a depressive-like state by an unpredictable chronic mild stress (UCMS) procedure to test the compounds' activity in the depression model, followed by measures of sucrose preference, FST, and locomotor activity. Levels of phosphorylated cyclic AMP response element-binding protein (p-CREB) and phosphorylated extracellular signal-regulated kinase (p-ERK1/2) were also determined. RESULTS:F15599 reduced immobility time in the FST over a wider dose-range (2 to 16 mg/kg po) than F13714 (2 and 4 mg/kg po), suggesting accentuated antidepressant-like properties in mice. F15599 did not disrupt long-term memory consolidation in the NOR at any dose tested, while F13714impaired memory formation, notably at higher doses (4-16 mg/kg). In UCMSmice, a single administration of F15599 and F13714 was sufficient to robustly normalize depressive-like behavior in the FST but did not rescue disrupted sucrose preference. Both F15599 and F13714 rescued cortical and hippocampal deficits in p-ERK1/2 levels of UCMSmice but did not influence the p-CREB levels. CONCLUSIONS: Our studies showed that 5-HT1A receptor biased agonists such as F13714 and especially F15599, due to its less pronounced side effects, might have potential as fast-acting antidepressants.
Authors: Marie-Bernadette Assié; Laurent Bardin; Agnès L Auclair; Elisabeth Carilla-Durand; Ronan Depoortère; Wouter Koek; Mark S Kleven; Francis Colpaert; Bernard Vacher; Adrian Newman-Tancredi Journal: Int J Neuropsychopharmacol Date: 2010-01-11 Impact factor: 5.176
Authors: Ronan Depoortère; Agnès L Auclair; Laurent Bardin; Francis C Colpaert; Bernard Vacher; Adrian Newman-Tancredi Journal: Eur Neuropsychopharmacol Date: 2010-05-21 Impact factor: 4.600
Authors: C B Filho; C R Jesse; F Donato; R Giacomeli; L Del Fabbro; M da Silva Antunes; M G de Gomes; A T R Goes; S P Boeira; M Prigol; L C Souza Journal: Neuroscience Date: 2015-01-12 Impact factor: 3.590
Authors: Sharon Cabanu; Fuencisla Pilar-Cuéllar; Paula Zubakina; Eva Florensa-Zanuy; Júlia Senserrich; Adrian Newman-Tancredi; Albert Adell Journal: Pharmaceuticals (Basel) Date: 2022-03-10